SEC Tracker
Get the app

Oric Pharmaceuticals ORIC

Oric Pharmaceuticals announces enozertinib trial updates

Item 7.01 Investor disclosure, Item 8.01 Other events

Form
8-K
Filed
Importance
Notable
  1. 26 patients treated with 80 mg enozertinib, 65% had brain metastases.
  2. 84% systemic ORR by investigator, 80% by BICR.
  3. Redwood-1 Phase 3 trial planned for 1H 2027 with 360 patients.
  4. No Grade 4 or 5 TRAEs, 23% had Grade 3 TRAEs.

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Oric Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Geron GERN public float $861M, Jun 30, 2025
  2. Intellia Therapeutics NTLA public float $869M, Jun 30, 2025
  3. Wave Life Sciences WVE public float $851M, Jun 30, 2025
  4. CorMedix CRMD public float $910M, Jun 30, 2025
  5. Niagen Bioscience NAGE public float $814M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.